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Heart failure remains one of the most common causes of 
morbidity and mortality worldwide. The advent of me-
chanical circulatory support devices has allowed signifi-
cant improvements in patient survival and quality of life 
for those with advanced or end-stage heart failure. We pro-
vide a general overview of past and current mechanical cir-
culatory support devices encompassing options for both 
short- and long-term ventricular support.
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Heart failure is one of the most common causes of morbid-
ity and mortality in the United States and worldwide. Al-
though transplantation is the gold standard for end-stage 
heart failure, it is limited by donor supply. In the United 
States, about 50 000 patients die each year from heart fail-
ure but the number of heart transplants remains steady at 
about 2000 per year (1). Moreover, transplantation is often 
not optimal or feasible for instances where short-term sup-
port may be adequate. While the mainstay of treatment of 
heart failure has traditionally been medical optimization, 
non-transplant surgical interventions have grown to play a 
key role in the care of these patients. Mechanical circulato-
ry support (MCS) options have grown exponentially since 
the first reports in the mid-twentieth century and are now 
considered a well-defined and accepted part of heart fail-
ure treatment strategies. These surgical procedures com-
prise an increasingly important part of the armamentari-
um of the modern cardiac surgeon.
Our intent in this review is to provide a targeted over-
view of the currently available options for device therapy 
for heart failure. While the entire spectrum of MCS is quite 
broad and includes techniques such as intra-aortic balloon 
pump counterpulsation (IABP), and extracorporeal mem-
brane oxygenation (ECMO), we will focus our discussion 
on ventricular assist devices (VAD) and total artificial heart 
(TAH) for the adult population.
HiStory
John Gibbon reported the first clinical use of MCS when he 
utilized cardiopulmonary bypass to repair an atrial septal 
defect in 1953 (1). The first VAD implantation was reported 
ten years later by Michael DeBakey in a patient with cardiac 
arrest following aortic valve replacement (2). This patient 
expired on postoperative day 4. DeBakey reported the first 
successful use of a VAD for bridge to recovery in 1966 in a 
patient who received support for 10 days and ultimately 
was discharged (3). The next several decades were marked 
by significant technological advancements in device de-
sign, spurred in part by initiatives funded by the United 
States National Heart, Lung, and Blood Institute (NHLBI) 
of the National Institutes of Health (NIH). 1984 marked the 
first successful implantation of a TAH, the Jarvik-7-100, by 
DeVries et al (4). The United States Food and Drug Admin-
istration (FDA) gave its first approval in 1994 for an LVAD to 
be used as a bridge-to-transplant (5).
Since then, continuous advances in device design have 
led to iterations of VADs that address and decrease 
complications such as infection, device failure, and throm-
boembolic events. These newer-generation devices com-
bined with improved surgical techniques have resulted in 
substantial improvements in clinical outcomes. In 2005, a 
national registry called the Interagency Registry for Me-
chanically Assisted Circulatory Support (INTERMACS) was 
created to serve as a central repository for MCS clinical out-
comes data. This prospective registry tracks real-time data 
points and has proven to be a vital component in under-
standing aggregate outcomes information for MCS pa-
tients.
GoaLS of device tHeraPy
The first, and most important, steps when considering MCS 
therapy are to clearly elucidate the goals of treatment and 
to expedite early evaluation by a multidisciplinary team. 
This allows for selection of the appropriate device and tim-
ing of intervention for each particular patient. There are 
five possible goals of MCS: 1. bridge-to-transplant (BTT), 2. 
destination therapy (DT), 3. bridge-to-recovery, 4. bridge-
to-decision, and 5. periprocedural support.
MCS therapy as BTT is utilized in patients deemed to be 
suitable transplant candidates but needing ventricular 
support while on the organ waiting list. Although VAD 
support is widely accepted as standard therapy for these 
patients, there are no uniform guidelines regarding tim-
ing of device placement. Thus, the decision to initiate VAD 
therapy must consider each individual patient’s operative 
risk of VAD placement, the estimated waiting time for an 
available organ, and the estimated mortality while on the 
waiting list. VAD support in these patients achieves reduc-
tion in pulmonary arterial pressures, increase in end-organ 
perfusion, and improvement from cardiac cachexia, which, 
in turn, result in the added benefit of improved transplant 
candidacy. Of the disadvantages and risks of VAD therapy, 
two are particularly relevant for BTT patients. First, because 
VAD implantation generally requires a major operation, 
any subsequent transplantation becomes a re-operation 
with its attendant risks. Second, exposure to blood prod-
ucts during MCS device implantation can result in sensiti-
zation to HLA antibodies, which could potentially make a 
donor match more difficult.
Patients who are not eligible for heart transplantation can 
be considered for MCS as DT. These patients are expect-
ed to receive MCS therapy for life, with the goals of pro-
longation of survival or improvement in quality of life. The 
benefits of MCS support as DT were substantiated in clini-
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cal trials (described below), demonstrating significant im-
provements in survival, functional ability, and quality of life 
with a DT VAD over optimal medical management.
Some patients experience reverse ventricular remodel-
ing after MCS therapy, ultimately resulting in improve-
ment in ventricular function to such a degree that allows 
for MCS device explantation. MCS used in these cases is 
considered bridge-to-recovery. These scenarios often in-
volve biventricular or sequential left followed by right VAD 
placement. Examples include viral myocarditis and giant 
cell myocarditis, both of which often resolve with tempo-
rary MCS support.
Bridge-to-decision MCS is utilized in settings of acute he-
modynamic compromise when there is insufficient time 
to permit a thorough evaluation of long-term MCS op-
tions. Often, the acutely ill patient may have multisystem 
organ failure and the benefit of long-term MCS is equiv-
ocal; in these cases, implantation of short-term MCS as 
bridge-to-decision can provide support until the patient’s 
status either improves sufficiently to justify conversion to 
a long-term device (as BTT or DT) or declines further, obvi-
ating the need for additional MCS therapy. Example clini-
cal scenarios can include postcardiotomy shock, acute 
exacerbation of chronic HF, myocardial infarction, and car-
diogenic shock after unsuccessful percutaneous coronary 
intervention.
Short term MCS can be used as periprocedural support for 
patients undergoing procedures in the cardiac catheteriza-
tion laboratory. One example is the use of IABP to augment 
coronary perfusion during high-risk percutaneous coro-
nary intervention (PCI). More recently, percutaneous LVADs 
have been used to provide mechanical assistance and may 
offer superior support when compared to IABP, particu-
larly during hemodynamic depression at the time of bal-
loon inflation in PCI. Percutaneous LVADs can be placed 
prophylactically before high-risk PCI or as rescue therapy 
in setting of periprocedural emergencies such as coronary 
dissection or cardiogenic shock. These MCS devices can be 
removed after completion of the procedure or left in place 
as a bridge to a definitive cardiac surgical operation.
It is important to note that these classifications are not 
fixed. A patient may receive MCS under one classification 
but changes in clinical status may modify that patient’s 
classification. For instance, a patient may receive an LVAD 
as BTT and then recover sufficient ventricular function such 
that the LVAD can be explanted, thus classifying MCS sup-
port as bridge-to-recovery. Similarly, a patient with a short-
term MCS device as bridge-to-decision who undergoes 
heart transplantation could then be considered as having 
had MCS as BTT.
device oPtionS
MCS devices can be classified and categorized by four fac-
tors: duration of support (short-term vs long-term), config-
uration of ventricular assist (biventricular vs univentricular), 
pump flow pattern (pulsatile vs continuous-flow), and lo-
cation of implantation (extracorporeal vs intracorporeal).
Short term device options
MCS is considered short-term when the duration of sup-
port is on the order of days to weeks. Currently available 
devices are listed in Table 1. The first short-term MCS de-
vice to receive FDA approval was the Abiomed BVS5000 
(ABIOMED Inc, Danvers, MA, USA). This device is a pulsa-
tile, pneumatically-driven pump with a large external con-
troller. In 1993, a multicenter, non-randomized clinical 
trial showed that in patients with postcardiotomy shock, 
implantation of the Abiomed BVS5000 resulted in 55% of 
patients weaning from support with 29% surviving to dis-
charge (6).
A recent addition to the armamentarium of short-term 
MCS options is the CentriMag (Thoratec Corp, Pleasanton, 
CA, USA). This device is an extracorporeal, continuous cen-
tabLe 1. Short-term mechanical circulatory support (McS) devices
device Manufacturer Mechanism assist Location
Intra-aortic balloon pump counterpulsation Multiple Counterpulsation Not applicable Not applicable
Extracorporeal membrane oxygenation Multiple Cardiopulmonary bypass Not applicable Not applicable
BVS5000 ABIOMED Pneumatic, pulsatile Right, left, or bi-ventricular Extracorporeal
CentriMag Thoratec Electric, centrifugal continuous Right, left, or bi-ventricular Extracorporeal
Impella CardiacAssist Electric, axial continuous Percutaneous; left Intracorporeal
TandemHeart ABIOMED Electric, centrifugal continuous Percutaneous; right, left, 
or bi-ventricular
Extracorporeal
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trifugal-flow pump with a magnetically levitated rotor and 
external controller. The CentriMag is capable of uni- or bi- 
ventricular support with flows up to 10 L/min (7,8). One of 
the key advantages of this device is its portability and ver-
satility. The CentriMag has been used to provide support 
for a period of days to weeks as a bridge-to-decision as 
well as bridge-to-transplant device (9,10). Frequently, the 
CentriMag is utilized for short-term right ventricular sup-
port in patients with long-term LVADs who demonstrate 
initial right heart dysfunction (11-13).
Two percutaneous devices are currently available for short-
term MCS. The TandemHeart (CardiacAssist Inc, Pittsburgh, 
PA, USA) is a continuous-flow centrifugal pump with an 
external controller capable of flow rates up to 5 L/min. 
This device is placed in the cardiac catheterization labo-
ratory with transseptal left atrial inflow via percutaneous 
femoral venous access and outflow through contralateral 
femoral arterial access. Though initially designed to pro-
vide temporary support for patients undergoing high-risk 
percutaneous cardiac interventions, the TandemHeart has 
also proven its utility in postcardiotomy heart failure and 
cardiogenic shock. Several studies have shown improve-
ments in hemodynamic parameters and cardiac indices 
with TandemHeart support in bridge-to-recovery and 
bridge-to-decision settings (14,15). The TandemHeart can 
be explanted either at the bedside when support is no lon-
ger needed or in the operating room at the time of trans-
plantation or implantation of a longer-term MCS device.
The Abiomed Impella (ABIOMED Inc) is another percuta-
neous short-term MCS option. This device is a continuous-
flow, axial pump with an external controller. There are two 
models, the Impella 2.5 and the Impella 5.0, with the num-
ber designating the maximal flow rate delivered: the Im-
pella 2.5 can deliver up to 2.5 L/min and the 5.0 up to 5.0 L/
min. The device is designed to rest across the aortic valve 
and pump blood from the left ventricle directly into the as-
cending aorta. The Impella 2.5 can be inserted percutane-
ously via the femoral vessels in the cardiac catheterization 
laboratory. In a randomized clinical trial comparing the Im-
pella to IABP counterpulsation, the Impella demonstrated 
superior hemodynamic support but 30-day mortality was 
similar in the two groups (16). One limitation of the Impella 
2.5 is that the maximal flow rate of 2.5 L/min may be inad-
equate for larger patients or scenarios that require more 
flow. The Impella 5.0 addresses this shortcoming by allow-
ing for greater flow rates. However, the 5.0 is a larger device 
which requires surgical cut-down for placement through a 
peripheral vessel.
The obvious advantage of percutaneous devices is implan-
tation performed without the need for surgery. Moreover, 
the insertion of percutaneous devices generally is techni-
cally less difficult and thus can be performed more expe-
ditiously, which can prove extraordinarily beneficial in the 
acute setting.
Long term device options
The early design of long-term MCS devices featured pulsa-
tile pump technology because pulsatility was believed to 
be necessary for organ perfusion and recovery. These early 
devices contained valves to allow for unidirectional blood 
flow and ventricular sacs that could produce a stroke vol-
ume of 65-85 mL. Because of the complexity and number 
tabLe 2. United States food and drug administration (fda) approved and investigational long-term mechanical circulatory support 
devices
device Manufacturer Mechanism assist Location
Novacor* World Heart Pneumatic, pulsatile Left Intracorporeal
HeartMate XVE* Thoratec Electric, pulsatile Left Intracorporeal
AB5000 ABIOMED Pneumatic, pulsatile Right, left, or bi-ventricular Paracorporeal
Paracorporeal Ventricular Assist Device Thoratec Pneumatic, pulsatile Right, left, or bi-ventricular Paracorporeal
Implantable Ventricular Assist Device Thoratec Pneumatic, pulsatile Right, left, or bi-ventricular Intracorporeal
HeartMate II Thoratec Electric, axial continuous Left Intracorporeal
HeartWare LVAS HeartWare Electric, centrifugal continuous Left Intracorporeal
Jarvik 2000 FlowMaker Jarvik Heart Electric, axial continuous Left Intracorporeal
HeartAssist 5 MicroMed Electric, axial continuous Left Intracorporeal
DuraHeart Terumo Electric, centrifugal continuous Left Intracorporeal
CardioWest TAH Syncardia Pneumatic, pulsatile Not applicable Intracorporeal
Abiomed TAH ABIOMED Electrohydraulic, pulsatile Not applicable Intracorporeal
*no longer commercially available in the United States.
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of mechanical parts, physical wear and tear of the device 
became a limiting factor in device durability (17-19). Sub-
sequent generations of these devices featured continuous 
flow pumps with fewer moving parts and improved dura-
bility. Studies demonstrated that continuous flow devic-
es provided improved outcomes with regards to survival, 
quality of life, functional capacity, and adverse events (20-
25). Table 2 lists currently available long-term MCS devices.
first generation vads
The Thoratec HeartMate XVE (Thoratec Corp) and Novacor 
LVAD system (WorldHeart Corp, Oakland, CA, USA) were 
among the earliest implantable VADs. The HeartMate XVE 
quickly became the first widely utilized LVAD worldwide. 
It is powered by an electrically driven pulsatile pump ca-
pable of generating up to 10 L/min of flow. It contains por-
cine valves in the inflow and outflow conduits to maintain 
unidirectional flow. The inflow cannula is attached to the LV 
apex, the outflow cannula to the ascending aorta, and the 
device itself is implanted behind the rectus sheath in the 
subcostal region or in the peritoneal cavity. The size of the 
device requires that the patient’s body surface area (BSA) 
be greater than 1.8 m2, thus excluding most children and 
small adults. The pump receives power from an external 
power source via a driveline that enters the body through 
the right side of the abdomen. The HeartMate XVE is con-
structed with textured blood-contacting surfaces that be-
come covered by a “pseudoneointimal” layer, eliminating 
the need for systemic anticoagulation. The HeartMate XVE 
is the only pump to date with this property, thus making 
this device particularly attractive for patients with a con-
traindication to systemic anticoagulation (17).
The HeartMate XVE was the first VAD to demonstrate MCS 
as a viable option for use as DT. In 2001, the Randomized 
Evaluation of Mechanical Assistance for the Treatment of 
Congestive Heart Failure (REMATCH) trial randomized 129 
patients with end-stage heart failure who were not candi-
dates for cardiac transplantation to receive either optimal 
medical management or implantation of the HeartMate 
XVE (17). Survival at one and two years was 52% and 23%, 
respectively, in the LVAD group vs 25% and 8% in the medi-
cal management cohort. In patients under the age of 60, 
the one-year survival was 74% with the LVAD compared 
to 33% with medical management. The most common 
causes of death in the LVAD group were infection (41%) 
and device failure (17%). Quality of life and functional ca-
pacity were also markedly improved in the LVAD cohort 
compared to the control patients. The results of this land-
mark trial led to FDA approval of the HeartMate XVE as 
the first VAD for DT. A follow-up study in patients with the 
HeartMate XVE, however, showed that the need for device 
exchange due to malfunction or failure approached nearly 
73% at two years, thus reinforcing the need for improved 
device design (26). While first generation LVADs helped to 
usher in the era of long-term MCS, they are rarely implant-
ed today as studies have shown superior outcomes with 
newer generation devices (17).
Other examples of first generation devices include the 
Abiomed AB5000, the Thoratec Paracorporeal Ventricular 
Assist Device (PVAD) II (Thoratec Corp), and the Thoratec 
Implantable Ventricular Assist Device (IVAD). All are pulsa-
tile pumps capable of bi- or uni- ventricular support. The 
Thoratec PVAD has been in clinical use for over 20 years 
and has the additional benefit of allowing patients to be 
discharged home with the device in place. In one series, 
47% of patients supported with a PVAD survived to dis-
charge while 68% underwent heart transplantation (27). 
The Thoratec IVAD is based on the PVAD but is smaller and 
completely implantable, thus permitting more mobility 
and independence after discharge. A portable driver in-
terface allows device evaluation and control by patients 
or their caregivers, and patients report an increase in their 
quality of life with this type of system (28).
Second generation vads
The Thoratec HeartMate II (HMII) is a second generation 
LVAD that received FDA approval in 2008 for BTT use. It is 
the most widely implanted LVAD to date with over 10 000 
patients worldwide. The HMII is composed of an electrical-
ly powered rotary continuous flow pump, where the only 
moving part is the axial rotor. This imparts tangential veloc-
ity and kinetic energy to the blood, resulting in generation 
of a net pressure rise across the pump. Power is supplied by 
an external source that connects via a percutaneous driv-
eline usually from the right side of the abdomen. The pump 
can generate flow rates of up to 10 L/min and is preload de-
pendent and afterload sensitive. Like the HeartMate XVE, 
the HMII has the inflow cannula connected to the LV apex 
and the outflow cannula to the ascending aorta. The HMII 
is also implanted in a preperitoneal pocket in the left sub-
costal space, but its smaller size allows it to be used in small-
er patients (BSA can be as low as 1.2 m2) than the XVE. As 
with all continuous flow devices, patients with the HMII do 
not have a palpable pulse. Some limitations of this type 
of device are hemolysis, ventricular suction events, and 
thrombus formation with pump stoppage (29,30).
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In 2007, the results of a multicenter trial investigating the 
HMII as BTT were published in the New England Journal of 
Medicine (29). This trial involved 26 centers enrolling 133 
patients with NYHA Class IV heart failure who were all on 
the active wait list for heart transplantation. All patients 
underwent HMII implantation. At the end of six months, 
75% of patients had either survived to transplant, had re-
covered sufficiently to survive explant of the HMII, or were 
still alive and awaiting transplant. There were no device 
failures, and functional capacity and quality of life also im-
proved significantly. Complications included bleeding ne-
cessitating surgery (31%), device-related infection (14%), 
stroke (8%), and pump thrombosis (1.5%) (29). A separate 
multicenter trial of 281 patients with the HMII showed six 
and twelve month survival of 82% and 73%, respectively 
(30). Furthermore, functional status had recovered mark-
edly by six months such that 83% of patients improved to 
NYHA class I or II. Pump replacement was required in 4% of 
patients (29,30).
The first report of post-FDA approval HMII outcomes was 
published in 2011 (31). This was a prospective study of 
the first 169 patients who received the HMII after it had 
become commercially available. This group was com-
pared to an INTERMACS cohort of 169 patients receiving 
another commercially available LVAD for BTT (135 with 
the Thoratec HeartMate XVE and 34 with the Thoratec 
IVAD, both pulsatile devices). At six months, 90% of the 
HMII patients had either survived to transplant, recov-
ered sufficiently to survive explant of the device, or were 
still alive and awaiting transplant vs 80% of the pulsatile 
pump group. Overall twelve month survival was 85% in 
the HMII group and 70% in the comparison cohort, and 
92% of the HMII patients were discharged home vs 75% 
of the pulsatile pump patients. This study again con-
firmed the superiority of continuous-flow VADs over pul-
satile devices as BTT.
In a separate trial investigating the HMII as DT support, 200 
patients at 38 different centers were randomized 2:1 to re-
ceive the HMII or the HeartMate XVE (32). These patients 
were not eligible to receive a heart transplant, had an LVEF 
of less than 25%, were NYHA class IIIb or IV, and were IABP-
dependent for 7 days or inotrope-dependent for 14 days. 
Ultimately, 133 patients received the HMII and 59 received 
the XVE. The primary endpoint was freedom from disabling 
stroke and freedom from reoperation for device malfunc-
tion at the end of two years. 46% of HMII patients reached 
the primary endpoint vs 11% of the XVE patients. Stroke 
occurred in 11% in the HMII group compared to 36% 
in the XVE group, and reoperation for device replacement 
was required in 10% of the HMII group vs 12% of the XVE 
group. While the rates of reoperation for pump replace-
ment were similar, the causes of device malfunction were 
notably different: bearing wear and valve degeneration or 
infection were culprits in the XVE, while broken percutane-
ous leads was most common in the HMII. One- and two-
year actuarial survival in the HMII group was 68% and 58%, 
respectively, vs 55% and 24% in the XVE group. This pivotal 
trial demonstrated superior outcomes and durability with 
the continuous-flow HMII over the pulsatile flow XVE for 
DT support.
In 2011, VAD centers began to report a perceived increase 
in the frequency of HMII pump exchanges due to throm-
bus, thus prompting an analysis of the INTERMACS data-
base. A review of 6910 patients from 132 institutions who 
received an HMII between 2008 and 2012 revealed an 
overall incidence of pump thrombus of 5.5% (33). There 
was a statistically significant increase in pump exchange 
or death due to pump thrombus during 2011 and 2012: 
the freedom from pump exchange or death due to throm-
bus decreased from 99% at 6 months before 2011 to 96% 
in 2011 and 94% in 2012. Overall survival of 80% at 1 year 
and 70% at 2 years, however, remained unchanged regard-
less of year of device implantation. No clear device-related 
or implantation technique-related etiology was identified 
as the cause of the increased pump thrombosis. Rather, 
risk factor analysis suggested a number of patient-related 
factors that may contribute to the risk of pump thrombo-
sis, and vigilant monitoring of anticoagulation parameters, 
thrombosis risk, hemolysis, infection, and mechanical fail-
ure was recommended.
Other second generation LVADs include the HeartAssist 
5 (MicroMed Cardiovascular Inc, Houston, TX, USA), Jar-
vik 2000 FlowMaker, and the HeartWare (HeartWare Inter-
national Inc, Framingham, MA, USA) left ventricular assist 
system (LVAS). The HeartAssist 5 is a small version of the 
Micromed DeBakey pump that can be implanted within 
the pericardial space. The Jarvik 2000 FlowMaker is also im-
planted in the pericardial space directly into the LV apex 
with an outflow attachment to the ascending or descend-
ing aorta. This portable device is capable of providing par-
tial support with flow rates up to 7 L/min and allows the 
patient to manually adjust the pump speed depending on 
activity level. One key advantage of the Jarvik 2000 is its 
small size: it is about the size of a C battery, significantly 
smaller than the Thoratec HMII. The Jarvik 2000 is currently 
in clinical trials and awaiting FDA approval.
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The HeartWare LVAS has a unique design that combines 
magnetic levitation and hydrodynamic suspension that 
eliminates any contact between the impellar and pump 
housing. It is implanted intrapericardially with LV apical in-
flow and outflow to the ascending aorta. The HeartWare 
LVAS operates at a fixed pump speed and is capable of pro-
ducing flow rates of 10 L/min. This device was studied in a 
BTT trial (ADVANCE) in the United States from 2008 to 2010 
(34). 140 patients with the HeartWare LVAS were compared 
to 499 patient controls from the INTERMACS registry who 
received a different LVAD as BTT. At six months, 92% of the 
HeartWare patients survived to transplant, recovered, and 
survived device explant, or were alive and still awaiting 
transplant compared to 90.1% of control patients. Six- and 
twelve-month survival was 94% and 90.6%, respectively, in 
the HeartWare group and 90.2% and 85.7% in the compari-
son group. The HeartWare LVAS received FDA approval for 
BTT in 2012 and is currently undergoing trials for DT use.
third generation vads
Third generation of devices are centrifugal continuous-
flow pumps with an impeller or rotor suspended in the 
blood flow path using either magnetic or hydrodynamic 
levitation. This eliminates component-to-component con-
tact, thus reducing frictional wear and heat generation and 
theoretically increasing device durability and reliability. The 
magnetic levitation systems are one of three types: exter-
nal motor-driven, direct-drive motor-driven, or bearingless 
motor. Third-generation LVADs are more widely used in Eu-
rope, where they reportedly comprise nearly 50% market 
share (25). Initial reports indicate non-inferiority of these 
third-generation LVADs when compared to second-gener-
ation devices (35).
Examples of third generation devices include the Terumo 
DuraHeart (Terumo Heart Inc, Ann Arbor, MI, USA) and 
Thoratec HeartMate III. The Terumo DuraHeart is commer-
cially available in Europe and is undergoing clinical trials 
in the United States. The device is a centrifugal continu-
ous flow pump that is implanted in a preperitoneal pocket 
and is capable of flow rates up to 8 L/min. Six and twelve 
month survival in a European BTT trial was 81% and 77%, 
respectively, with no pump failure or thrombosis during 
an average support duration of eight months. The most 
common adverse events were neurological complications 
(27%), right heart failure (27%), and infection (18%) (36). 
The Thoratec HeartMate III is a centrifugal pump, which is 
in clinical trials. It remains to be seen whether these third 
generation devices provide substantial improvement in 
outcomes and adverse events over currently available sec-
ond generation continuous flow VADs.
total artificial heart
The quest for a TAH began with the advent of MCS devices. 
Conceptually, the TAH is quite attractive as it offers the abil-
ity to replace the entire failing heart. The successful design 
and implementation of a TAH in clinical practice, however, 
has been much more elusive. Furthermore, the rapid ex-
pansion of VAD technology has overshadowed TAH devel-
opment. As a result, the majority of patients with advanced 
heart failure can be successfully managed with an LVAD 
or BIVAD and the necessity of a TAH is debatable. The cur-
rent indications for a TAH are limited and include severe 
bi-ventricular failure, myocardial rupture, post-transplant 
rejection, LV thrombus, restrictive cardiomyopathy (amy-
loidosis and hypertrophic cardiomyopathy), and refractory 
ventricular dysrhythmia.
At present, the only TAH that is FDA approved is the Cardio-
West TAH (Syncardia Systems Inc, Tucson, AZ, USA), a pneu-
matically powered pulsatile dual chamber device. Two per-
cutaneous drivelines connect the TAH to an external power 
source. The patient must remain in hospital, although the 
recent development of a portable wearable power source, 
the Freedom Driver, may ultimately permit discharge to 
home. The Freedom Driver allows considerably greater 
mobility and is currently undergoing trials. The design of 
the CardioWest device consists of four prosthetic tilting 
disk valves and two 70 cc pumping chambers that can pro-
duce flow rates up to 9.5 L/min. The relatively large size of 
the device requires a minimal body surface area of 1.7 m2 
(37,38). There have been nearly 1000 implants worldwide. A 
multicenter BTT trial compared 81 critically ill patients with 
biventricular failure who received the CardioWest TAH to a 
35-patient historical control group who received medical 
therapy alone (39). Survival to transplantation was 79% in 
the CardioWest TAH cohort and 46% in the control group. 
Post-transplantation survival was also superior in the TAH 
group, with 86% at one year and 64% at five years vs 69% 
and 34% in the control patients. The CardioWest patients 
also showed substantial improvement in hepatic and re-
nal function parameters within weeks of TAH implantation. 
Adverse events included significant bleeding (28%), drive-
line infection (21%), stroke with residual neurologic deficit 
(0.07%), and device malfunction (0.01%).
The Abiomed TAH (ABIOMED Inc) is available in the 
United States under an FDA humanitarian device 
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exemption. This TAH is a completely implantable titani-
um and plastic dual chamber pump utilizing an electro-
hydraulic mechanism to alternate ejection between the 
two chambers. Because the entire device is intracorporeal, 
there is no external driveline. Implantation of the Abiomed 
TAH began in 2001 under an FDA investigational device 
exemption. A total of 14 patients received the device with 
the longest duration of support being 512 days (40).
concLUSionS
There have been remarkable advancements in MCS op-
tions since the first days of cardiopulmonary support. 
Landmark trials such as REMATCH firmly established MCS 
as a viable, effective treatment strategy for advanced heart 
failure. With MCS, patients with end stage heart disease, 
regardless of transplant eligibility, are now living longer 
than ever with improved quality of life. Collaborative data-
base registries such as INTERMACS provide contemporary, 
real-time data to assist in the optimization of risk stratifica-
tion and patient selection. Evolution of device design will 
hopefully continue to decrease complications and result in 
smaller, portable, and more durable device options.
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